Literature DB >> 8978719

Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors.

M Y Zhu1, G A Ordway.   

Abstract

To investigate the regulation of norepinephrine transporters (NETs) in vitro, we measured the binding of the NET-selective ligand [3H]nisoxetine in homogenates of PC12 cells after exposure of intact cells to the NET inhibitor desipramine (DMI). A 3-day exposure of PC12 cells to DMI robustly reduced the Bmax, but not the KD, of [3H]nisoxetine binding to NETs. Reduction of the binding of [3H]nisoxetine was dependent on both the concentration of DMI and the time of exposure to DMI. Reduction of [3H]nisoxetine binding to NETs produced by a 1-day exposure to DMI reverted to preexposure levels 48 h after cessation of DMI exposure. Similar down-regulation of NETs was found when PC12 cells were exposed to another NET-selective drug, nisoxetine, which is structurally unrelated to DMI. In contrast, exposure of cells to the serotonin transporter-selective drug citalopram, or the NET substrate norepinephrine, had no effects on the binding of [3H]nisoxetine to NETs. The down-regulation of NETs was paralleled by a DMI-induced reduction in the uptake of [3H]norepinephrine in intact PC12 cells. It can be inferred from these data that inhibitors of the NET can down-regulate NETs directly, and do so in the absence of changes in the synaptic concentration of norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978719     DOI: 10.1046/j.1471-4159.1997.68010134.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles.

Authors:  Prashant Mandela; Michelle Chandley; Yao-Yu Xu; Meng-Yang Zhu; Gregory A Ordway
Journal:  Neurochem Int       Date:  2010-02-20       Impact factor: 3.921

2.  Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine content.

Authors:  Erica A Wehrwein; Lindsay M Parker; Anna A Wright; John M Spitsbergen; Martin Novotny; Dagmar Babankova; Greg M Swain; Beth A Habecker; David L Kreulen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-18       Impact factor: 3.619

3.  Involvement of PI3K/Akt/FoxO3a and PKA/CREB Signaling Pathways in the Protective Effect of Fluoxetine Against Corticosterone-Induced Cytotoxicity in PC12 Cells.

Authors:  Bingqing Zeng; Yiwen Li; Bo Niu; Xinyi Wang; Yufang Cheng; Zhongzhen Zhou; Tingting You; Yonggang Liu; Haitao Wang; Jiangping Xu
Journal:  J Mol Neurosci       Date:  2016-07-13       Impact factor: 3.444

4.  Chronic desipramine treatment alters tyrosine hydroxylase but not norepinephrine transporter immunoreactivity in norepinephrine axons in the rat prefrontal cortex.

Authors:  Susan L Erickson; Anjalika R Gandhi; Josephine K Asafu-Adjei; Allan R Sampson; LeeAnn Miner; Randy D Blakely; Susan R Sesack
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-06       Impact factor: 5.176

Review 5.  Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression.

Authors:  Joanne J Liu; Adrienne Hezghia; Saame Raza Shaikh; Joshua F Cenido; Ruth E Stark; J John Mann; M Elizabeth Sublette
Journal:  Neuropsychopharmacology       Date:  2018-06-28       Impact factor: 7.853

6.  Differentiation of rodent behavioral phenotypes and methylphenidate action in sustained and flexible attention tasks.

Authors:  Richard Chu; Jed Shumsky; Barry D Waterhouse
Journal:  Brain Res       Date:  2015-12-10       Impact factor: 3.252

7.  (R)-N-Methyl-3-(3-(125)I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters.

Authors:  Balagopal Lakshmi; Mei-Ping Kung; Brian Lieberman; Jun Zhao; Rikki Waterhouse; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

8.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

9.  The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.

Authors:  Meng-Yang Zhu; Patrick B Kyle; Arthur S Hume; Gregory A Ordway
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

10.  MicroRNAs 29b and 181a down-regulate the expression of the norepinephrine transporter and glucocorticoid receptors in PC12 cells.

Authors:  Maoxian Deng; Turan Tufan; Muhammad U Raza; Thomas C Jones; Meng-Yang Zhu
Journal:  J Neurochem       Date:  2016-09-22       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.